Free Trial

Y Intercept Hong Kong Ltd Acquires 33,682 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Inari Medical logo with Medical background

Y Intercept Hong Kong Ltd lifted its position in Inari Medical, Inc. (NASDAQ:NARI - Free Report) by 316.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,318 shares of the company's stock after buying an additional 33,682 shares during the period. Y Intercept Hong Kong Ltd owned about 0.08% of Inari Medical worth $1,828,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of NARI. Wealth Enhancement Advisory Services LLC lifted its stake in Inari Medical by 7.7% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 4,852 shares of the company's stock valued at $234,000 after buying an additional 348 shares in the last quarter. Arizona State Retirement System boosted its stake in Inari Medical by 2.5% in the 2nd quarter. Arizona State Retirement System now owns 14,602 shares of the company's stock worth $703,000 after purchasing an additional 358 shares during the period. Nisa Investment Advisors LLC increased its holdings in Inari Medical by 83.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company's stock worth $46,000 after purchasing an additional 435 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Inari Medical by 67.2% in the 3rd quarter. GAMMA Investing LLC now owns 1,177 shares of the company's stock valued at $49,000 after purchasing an additional 473 shares during the period. Finally, KBC Group NV lifted its holdings in shares of Inari Medical by 39.0% in the third quarter. KBC Group NV now owns 1,774 shares of the company's stock valued at $73,000 after purchasing an additional 498 shares in the last quarter. 90.98% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

NARI has been the subject of a number of research reports. Stifel Nicolaus started coverage on Inari Medical in a report on Tuesday, September 17th. They set a "hold" rating and a $50.00 price objective for the company. Canaccord Genuity Group lifted their price objective on shares of Inari Medical from $71.00 to $74.00 and gave the company a "buy" rating in a report on Tuesday, October 29th. Leerink Partnrs upgraded shares of Inari Medical to a "hold" rating in a report on Tuesday, September 3rd. Piper Sandler raised their target price on shares of Inari Medical from $50.00 to $52.00 and gave the company a "neutral" rating in a research report on Tuesday, October 29th. Finally, Truist Financial boosted their price target on shares of Inari Medical from $46.00 to $50.00 and gave the stock a "hold" rating in a research report on Tuesday, October 29th. Six investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $58.89.

View Our Latest Stock Analysis on Inari Medical

Inari Medical Stock Performance

NASDAQ:NARI traded up $3.16 during mid-day trading on Wednesday, hitting $58.21. The stock had a trading volume of 1,667,073 shares, compared to its average volume of 985,798. Inari Medical, Inc. has a twelve month low of $36.73 and a twelve month high of $67.13. The stock has a market cap of $3.41 billion, a price-to-earnings ratio of -43.12 and a beta of 0.97. The company's 50 day simple moving average is $48.14 and its 200 day simple moving average is $47.88.

Insider Activity

In other Inari Medical news, CFO Mitch C. Hill sold 3,000 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $45.13, for a total value of $135,390.00. Following the transaction, the chief financial officer now directly owns 179,600 shares of the company's stock, valued at $8,105,348. This represents a 1.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William Hoffman sold 60,000 shares of the firm's stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $51.16, for a total transaction of $3,069,600.00. Following the sale, the director now owns 501,233 shares of the company's stock, valued at $25,643,080.28. This trade represents a 10.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 186,000 shares of company stock valued at $8,990,990 over the last three months. Insiders own 10.60% of the company's stock.

About Inari Medical

(Free Report)

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.

Further Reading

Institutional Ownership by Quarter for Inari Medical (NASDAQ:NARI)

→ A conspiracy Trump won’t unseal (From Porter & Company) (Ad)

Should you invest $1,000 in Inari Medical right now?

Before you consider Inari Medical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inari Medical wasn't on the list.

While Inari Medical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Broadcom Hits $1 Trillion – Can This AI Powerhouse Go Higher?
SoundHound Stock Explodes Again – Is a Major Breakout Coming?
How Fintech Strategy at FinWise Bancorp and CEO Vision Are Driving 78% Gains

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines